Induction of micronucleated erythrocytes by MEA, AET, WR-2721 and X-rays.

[1]  L. Mazur,et al.  Temporary changes in acid phosphatase activity in the organs of mice treated with AET or MEA prior to 60Co gamma-irradiation. , 1993, Folia biologica.

[2]  G. Jagetia.  Radiation-induced chromosomal aberrations in the bone marrow of mice exposed to various doses of gamma radiation , 1993, Radiation and environmental biophysics.

[3]  J. Phillips,et al.  DNA double‐strand breaks in mutagenesis , 1993, Environmental and molecular mutagenesis.

[4]  J. Savage.  Update on target theory as applied to chromosomal aberrations , 1993, Environmental and molecular mutagenesis.

[5]  G. Hoffmann,et al.  Modulation of the clastogenic activity of ionizing radiation and bleomycin by the aminothiol WR‐1065 , 1993, Environmental and molecular mutagenesis.

[6]  A. Brooks,et al.  Metaphase chromosome aberrations as markers of radiation exposure and dose. , 1993, Journal of toxicology and environmental health.

[7]  G. Krishna,et al.  Simultaneous evaluation of clastogenicity, aneugenicity and toxicity in the mouse micronucleus assay using immunofluorescence. , 1992, Mutation research.

[8]  I. Basic,et al.  Antimutagenic Effects of Radioprotector WR-2721 Against Fission-spectrum Neutrons and 60Co γ-rays in Mice , 1992 .

[9]  E. Ludewig,et al.  The micronucleus test in pigs: induction of micronuclei in polychromatic erythrocytes by various doses of X-rays. , 1991, Mutation research.

[10]  P. Uma Devi,et al.  Radioprotective effect of combinations of WR-2721 and mercaptopropionylglycine on mouse bone marrow chromosomes. , 1990, Radiation research.

[11]  M C Cimino,et al.  The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. , 1990, Mutation research.

[12]  K. Krohn,et al.  Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins. , 1990, Biochemical pharmacology.

[13]  M. Allalunis-Turner.  Reduced bone marrow pO2 following treatment with radioprotective drugs. , 1990, Radiation research.

[14]  G. Jagetia,et al.  Frequency of micronucleated cells in the mouse bone marrow after exposure to various doses of gamma-radiation. , 1990, Mutation research.

[15]  R. Neta,et al.  Advances in radioprotection through the use of combined agent regimens. , 1990, International journal of radiation biology.

[16]  P. Uma Devi,et al.  Mouse bone-marrow response to low doses of whole-body gamma irradiation: induction of micronuclei. , 1990, International journal of radiation biology.

[17]  M. Allalunis-Turner,et al.  Induction of marrow hypoxia by radioprotective agents. , 1989, Radiation research.

[18]  S. De Flora,et al.  Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview. , 1988, Mutation research.

[19]  J. Dominitz,et al.  Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation. , 1988, Toxicology.

[20]  L. Shaw,et al.  Pharmacokinetics of WR-2721. , 1988, Pharmacology & therapeutics.

[21]  L. Milas,et al.  Radioprotective action of aminothiols in vitro and in vivo: comparison between effects on DNA damage and cell survival. , 1988, Pharmacology & therapeutics.

[22]  K. Held.  Models for thiol protection of DNA in cells. , 1988, Pharmacology & therapeutics.

[23]  R. C. Fahey,et al.  Protection of DNA by thiols. , 1988, Pharmacology & therapeutics.

[24]  C. Greenstock.  Radiation chemical considerations for the radioprotection of cellular targets. , 1988, Pharmacology & therapeutics.

[25]  J. Dominitz,et al.  Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice , 1987, Pharmacology Biochemistry and Behavior.

[26]  G. Köteles,et al.  The present state and perspectives of micronucleus assay in radiation protection. A review. , 1987, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[27]  B. Hilaris,et al.  Radiation therapy of gynecological cancer , 1987 .

[28]  D. Gatehouse,et al.  The use of a simple haematoxylin and eosin staining procedure to demonstrate micronuclei within rodent bone marrow. , 1986, Mutation research.

[29]  G. L. Floersheim,et al.  Protection against ionising radiation and synergism with thiols by zinc aspartate. , 1986, The British journal of radiology.

[30]  J. Kim,et al.  Radiosensitizers and protectors. , 1984, Cancer investigation.

[31]  F. Gilbert,et al.  Homogeneously staining regions in direct preparations from human neuroblastomas. , 1982, Cancer research.

[32]  H. Thames,et al.  Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. , 1982, Cancer research.

[33]  J. Heddle,et al.  Chromosomal aberrations and bone marrow toxicity. , 1981, Environmental health perspectives.

[34]  C. Bloor,et al.  Protection of normal tissue against late radiation injury by WR-2721. , 1981, Radiation research.

[35]  M. Srinivasan,et al.  Ineffectiveness of 2-mercaptopropionylglycine in increasing survival of mice after gamma irradiation either alone or in combination with 2-aminoethyl isothiuronium bromide hydrobromide. , 1980, Journal of radiation research.

[36]  W Schmid,et al.  The micronucleus test. , 1975, Mutation research.

[37]  H. Landahl,et al.  Dose reduction factor for radiation lethality in mice as a function of the dose of mercaptoethylamine. , 1970, Radiation research.

[38]  I. Filippovich,et al.  EFFECT OF MODIFYING FACTORS ON RADIOSENSITIVE BIOCHEMICAL REACTIONS. , 1970 .

[39]  J. Yuhas.  Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses. , 1970, Radiation research.

[40]  H. Scheraga,et al.  A Second Right-handed Helical Structure with the Parameters of the Pauling–Corey α-helix , 1967, Nature.

[41]  P. E. Brown,et al.  Mechanism of Action of Aminothiol Radioprotectors , 1967, Nature.